Abstracts tagged "infliximab"

Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 1122 • 2016 ACR/ARHP Annual Meeting
Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice
Qi Quan Huang¹, Robert Birkett¹, Elyssa L Roberts² and Richard M. Pope³, ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²northwestern University, Chicago, IL, ³Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Macrophages in rheumatoid arthritis (RA) synovium produce high levels of inflammatory cytokines/chemokines and play the pivotal role in promoting inflammation and joint destruction. Treatment…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting
Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Dalton Sholter¹, Proton Rahman², Maqbool Sheriff³, Michel Zummer⁴, Suneil Kapur⁵, Philip Baer⁶, Michael Starr⁷, John Kelsall⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Brendan Osborne¹¹, Karina Maslova¹², Cathy Tkaczyk¹¹, Francois Nantel¹³ and Allen J Lehman¹², ¹University of Alberta, Edmonton, AB, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁶Independent Rheumatology Practice, Scarborough, ON, Canada, ⁷Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Ignacio Ortea¹, Bernd Roschitzki², Eva Tomero³, Juan G. Ovalles-Bonilla⁴, Javier Lopez-Longo⁵, Inmaculada de la Torre⁵, Isidoro Gonzalez-Alvaro⁶, Juan J Gomez-Reino⁷ and Antonio Gonzalez⁸, ¹Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, ²Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Gregorio Marañon Hospital, Madrid, Spain, ⁶Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, ⁷Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁸Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Jeffrey R. Curtis¹, Ying Shan², Joel M. Kremer³, Katherine Saunders⁴, Dennis Parenti⁵ and Shelly Kafka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²UMass Memorial Medical Center, Worcester, MA, ³Albany Medical College, Albany, NY, ⁴Corrona LLC, Atlanta, GA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
Abstract Number: 1273 • 2015 ACR/ARHP Annual Meeting
Uptake of the First Biosimilar Infliximab Since Its Approval in South Korea
Seoyoung C. Kim¹, Nam-Kyong Choi², Joongyub Lee², Kyoung-Eun Kwon³, Wesley Eddings⁴, Yoon-Kyoung Sung⁵, Hong Ji Song⁶, Aaron K. Kesselheim⁴ and Daniel H. Solomon⁷, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University College of Medicine, Seoul, South Korea, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Hospital for Rheumatic Disease, Hanyang Univ Medical Center, Seoul, South Korea, ⁶Hallym University Sacred Heart Hospital, Anyang, South Korea, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Development of tumor necrosis factor (TNF) inhibitors has been a major advance in treatment of systemic inflammatory diseases, such as rheumatoid arthritis. While TNF…
Abstract Number: 1302 • 2015 ACR/ARHP Annual Meeting
Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids
Gülsah Akdemir¹, Arie E. van der Bijl², Badelog J.E. de Lange-Brokaar³, T. W. J. Huizinga¹, Cornelia F. Allaart¹ and Margreet Kloppenburg³, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Isala Klinieken, Zwolle, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To evaluate synovial inflammation on magnetic resonance imaging (MRI) before treatment and changes after treatment with intra-articular (i.a.) infliximab (IFX) or methylprednisolone (MP) injections…
Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting
What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Rafat Faraawi¹, Raman Joshi², William G Bensen³, Denis Choquette⁴, Wojciech Olsynzynski⁵, Regan Arendse⁵, Maqbool Sheriff⁶, Proton Rahman⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, Cathy Tkaczyk¹¹ and Brendan Osborne¹¹, ¹McMaster University, Hamilton, ON, Canada, ²William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, ON, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Medicine, Memorial University, St John's, NF, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…
Abstract Number: 2866 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period
Proton Rahman¹, Michel Zummer², William G Bensen³, Isabelle Fortin⁴, Dalton Sholter⁵, Milton F. Baker⁶, Regan Arendse⁷, Eliofotisti Psaradellis⁸, Emmanouil Rampakakis⁹, Francois Nantel¹⁰, Allen J Lehman¹⁰, Cathy Tkaczyk¹¹, Karina Maslova¹⁰ and Brendan Osborne¹¹, ¹Medicine, Memorial University, St John's, NF, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶VIHA, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy and tolerability of golimumab (GLM) in patients with psoriatic arthritis (PsA) has been demonstrated in several controlled clinical trials. Longitudinal observational studies…
Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Msataka Kuwana⁵, Mitsuhiro Takeno⁶ and Yoshiaki Ishigatsubo⁷, ¹Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁵Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, ⁷Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Boulos Haraoui¹, Maqbool Sheriff², Majed Khraishi³, Michael Starr⁴, John Kelsall⁵, Milton Baker⁶, Regan Arendse⁷, Sanjay Dixit⁸, William Bensen⁹, Philip Baer¹⁰, Rafat Faraawi⁸, Emmanouil Rampakakis¹¹, John S. Sampalis¹¹, Susan Otawa¹², Allen J Lehman¹², Francois Nantel¹³ and May Shawi¹³, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹⁰Private Practice, Scarborough, ON, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2269 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of High Dose Infliximab in the Treatment of Uveitis in Pediatric Patients
Liza Mariel Bermudez¹, Patricia Irigoyen¹, Anca Askanase², Michael Weiss³, Joyce Hui-Yuen¹, Amy J. Starr², Lisa F. Imundo⁴, Andrew H. Eichenfield² and Josephine Isgro¹, ¹Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Division of Ophthalmology Uveitis Service College of Physician And Surgeons of Columbia University, New York, NY, ⁴Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY
Background/Purpose Chronic uveitis, an inflammatory eye disease, is a leading causes of childhood blindness and often has a chronic recurrent course. This study reviews the efficacy and safety of high…
Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting
Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Frank I Scott¹, Ronac Mamtani¹, Colleen Brensinger¹, Kevin Haynes², Zelma ChiesaFuxench¹, Huifeng Yun³, Jie Zhang⁴, Lang Chen⁵, Fenglong Xie⁶, David Margolis⁷, James D. Lewis² and Jeffrey R. Curtis⁸, ¹University of Pennsylvania, Philadelphia, PA, ²Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁴Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].